3645 results for «786»
3645 results
Insight from new evidence for complex PCI: value of imaging (CHIP IVUS) and left ventricular support (CHIP BCIS 3)
21 May 2026 – From EuroPCR 2026
This session reviews the impact of recent evidence on complex PCI, highlighting the value of intracoronary imaging (CHIP IVUS trial) and left ventricular assist devices (CHIP BCIS 3 trial). Through case discussions, participants reflect on how these innovations influence daily clinical practice and enhance procedural planning...
Risk stratification and reperfusion strategies for acute and subacute pulmonary embolism
21 May 2026 – From EuroPCR 2026
Focus on risk stratification and reperfusion strategies for acute and subacute pulmonary embolism through this session. It discusses the impact of elective endovascular therapies in intermediate-high risk patients, intraprocedural complications, and early mortality associated with catheter interventions. Additionally, it reviews real-world outcomes of catheter-directed therapy, national...
Challenging procedures for bifurcation lesions
22 May 2026 – From EuroPCR 2026
Explore a series of challenging cases in coronary bifurcation interventions, highlighting complex decision-making scenarios, pharmaco-invasive strategies guided by IVUS, and tailored techniques for reintervention. Emphasis is placed on imaging-guided PCI and simplifying complex double bifurcation and long lesion treatments to optimize patient outcomes.
Beyond stent: use of DCB in CTO
22 May 2026 – From EuroPCR 2026
This session focuses on the innovative use of drug-coated balloons (DCB) in chronic total occlusion (CTO) interventions. It reviews combined plaque modification techniques, complex multivessel PCI cases involving CTOs, and strategy considerations such as hybrid therapy versus full metal jacket, emphasizing vessel biology preservation during revascularisation.
Real-world outcomes with the PASCAL Platform in TR
03 Dec 2021
The PASCAL platform, comprising the PASCAL and PASCAL Ace implants, received its CE mark for TR in May 2020 and has been shown to be an effective and safe treatment option for patients with TR.3,4,6 Professor Jörg Hausleiter and Dr Mirjam Wild now describe their single-centre experience...
